Press coverage about Luminex (NASDAQ:LMNX) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Luminex earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave media stories about the medical instruments supplier an impact score of 46.7245241359838 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
- Luminex Co. (LMNX) Receives Consensus Recommendation of “Hold” from Analysts (americanbankingnews.com)
- Luminex Corp. – Value Analysis (NASDAQ:LMNX) : December 6, 2017 (finance.yahoo.com)
- Luminex Corp. breached its 50 day moving average in a Bearish Manner : LMNX-US : December 5, 2017 (finance.yahoo.com)
- Comparing Luminex (LMNX) & Its Peers (americanbankingnews.com)
Luminex (NASDAQ LMNX) opened at $20.54 on Friday. Luminex has a 1-year low of $17.68 and a 1-year high of $22.42. The company has a market cap of $904.88, a price-to-earnings ratio of 35.45, a P/E/G ratio of 2.58 and a beta of 0.19.
Several equities research analysts have recently issued reports on LMNX shares. Zacks Investment Research raised shares of Luminex from a “hold” rating to a “strong-buy” rating and set a $22.00 price objective for the company in a research report on Thursday, August 24th. ValuEngine upgraded shares of Luminex from a “sell” rating to a “hold” rating in a report on Wednesday, September 6th. Jefferies Group restated a “hold” rating and set a $21.00 target price on shares of Luminex in a report on Friday, October 20th. TheStreet upgraded shares of Luminex from a “c+” rating to a “b-” rating in a report on Wednesday, November 1st. Finally, BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company. Luminex has an average rating of “Hold” and an average price target of $20.00.
In other Luminex news, Director G Walter Loewenbaum II sold 50,000 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $21.79, for a total value of $1,089,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 6.90% of the company’s stock.
Luminex Company Profile
Luminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company’s products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments.
Receive News & Ratings for Luminex Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex Co. and related companies with MarketBeat.com's FREE daily email newsletter.